Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹38,724 Cr
Revenue (TTM)
₹9,505 Cr
Net Profit (TTM)
₹910 Cr
ROE
11.9 %
ROCE
15.3 %
P/E Ratio
42.6
P/B Ratio
5
Industry P/E
28.4
EV/EBITDA
19.5
Div. Yield
0.3 %
Debt to Equity
0.2
Book Value
₹307.1
EPS
₹41.3
Face value
1
Shares outstanding
253,704,218
CFO
₹7,421.05 Cr
EBITDA
₹9,276.53 Cr
Net Profit
₹5,444.40 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| 7.4 | 4.1 | 7.0 | 12.1 | 24.9 | 10.6 | 18.5 |
|
BSE Healthcare
| -2.3 | -1.4 | -3.4 | 3.5 | 25.4 | 15.6 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
| -16.2 | 51.4 | 32.0 | -22.2 | -0.6 | 92.3 | 39.2 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ipca Laboratories
|
1,524.3 | 38,724.1 | 9,504.5 | 947.8 | 15.9 | 14.6 | 42.6 | 5.0 |
| 26,715.0 | 56,544.3 | 6,824.1 | 1,524.1 | 25.9 | 37 | 37.1 | 12.9 | |
| 5,268.0 | 62,916.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 26.5 | 4.5 | |
| 1,290.6 | 74,586.5 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.4 | 2.1 | |
| 380.4 | 61,367.6 | 16,827.4 | 629.6 | 9.6 | -0.1 | 101.6 | 1.6 | |
| 2,403.8 | 40,852.3 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40 | 20.4 | |
| 2,332.8 | 1,05,535.9 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,012.5 | 81,998.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 46.1 | 5.2 | |
| 1,776.8 | 4,24,682.3 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 38.9 | 5.2 | |
| 894.3 | 89,585.0 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.1 | 3.4 |
2 min read•By Value Research
Which stocks are vulnerable to Brexit?
4 min read•By Kumar Shankar Roy
5 min read•By Vikas Vardhan
3 min read•By Research Desk
5 min read•By Value Research
3 min read•By Research Desk
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of... anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. Read more
Incorporated
1949
Chairman
Premchand Godha
Managing Director
Pranay Godha
Group
Ipca Laboratories
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Ipca Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Ipca Laboratories Ltd is ₹1,524.30 (NSE) and ₹1,522.20 (BSE) as of 20-Mar-2026 13:44 IST. Ipca Laboratories Ltd has given a return of 24.87% in the last 3 years.
The P/E ratio of Ipca Laboratories Ltd is 42.56 times as on 20-Mar-2026, a 50 premium to its peers’ median range of 28.40 times.
The P/B ratio of Ipca Laboratories Ltd is 4.97 times as on 20-Mar-2026, a 11 premium to its peers’ median range of 4.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
51.63
|
5.48
|
|
2024
|
57.39
|
4.96
|
|
2023
|
43.62
|
3.52
|
|
2022
|
30.45
|
4.93
|
|
2021
|
10.59
|
5.13
|
The 52-week high and low of Ipca Laboratories Ltd are Rs 1,624.00 and Rs 1,168.20 as of 20-Mar-2026.
Ipca Laboratories Ltd has a market capitalisation of ₹ 38,724 Cr as on 20-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Ipca Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-20.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.